7 July 2016 SATVI wins grant to study Immunological significance of QuantiFERON TB Gold In-tube reversions

7 Jul 2016 - 12:30

Dr Elisa Nemes, SATVI Senior Research Officer has just been awarded a grant to study the adaptive and innate immune responses associated with spontaneous reversion of QuantiFERON In Tube assay (QFT), used to determine if a person is infected with Mycobacterium tuberculosis (M.tb). This study will contribute to the interpretation of QFT serial testing, develop novel and more robust immunological assays to diagnose M.tb infection and monitor vaccine-induce immune responses relevant to stop TB transmission.

Results will generate hypotheses about immune protection from M.tb infection.



Bionote of Dr Elisa Nemes

Elisa completed her PhD in HIV-specific T cell immunology in Italy and France. She then worked on paediatric immune responses to HIV and TB in Cameroon. She joined SATVI in 2011, where she has been involved in basic immunology studies, clinical trials of new TB vaccines and studies of host correlates of risk of TB disease in BCG-vaccinated infants and of BCG/TB immune reconstitution inflammatory syndrome in HIV+ children.

Research Profile. Click here.